Compositions and methods for treating and preventing graft versus host disease
View Patent ↗Provided herein are compositions and methods for administering bacterial strains to reduce GvHD and improve survival after allogeneic BMT.
1. A method of treating Graft versus Host Disease (GvHD), the method comprising administering to the digestive tract of a subject in need thereof a therapeutically effective amount of a bacterial composition, the bacterial composition comprising bacterial strains comprising 16S rDNA sequences of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO: 11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ ID NO:16, and SEQ ID NO:17, wherein said bacterial composition is administered prior to and following a bone marrow transplant.
2. The method of claim 1 , wherein one or more of the bacterial strains does not have an antibiotic resistance gene.
3. The method of claim 1 , wherein one or more of the bacterial strains is not resistant to vancomycin.
4. The method of claim 1 , wherein one or more of the bacterial strains produces butyrate.
5. The method of claim 1 , wherein the method does not include the administration of an antibiotic.
6. The method of claim 1 , wherein the bacterial composition is administered every other day for 14 days prior to bone marrow transplant.
7. The method of claim 1 , wherein the bacterial composition is administered every other day for at least 21 days after bone marrow transplant.
8. The method of claim 1 , wherein the subject has chronic GvHD.
9. The method of claim 1 , wherein the subject has acute GvHD.
10. The method of claim 1 , wherein the bacterial composition is a pharmaceutical composition.
11. The method of claim 10 , wherein the pharmaceutical composition comprises a pharmaceutical acceptable excipient.
12. The method of claim 10 , wherein the pharmaceutical composition is formulated for oral administration.
13. The method of claim 10 , wherein the pharmaceutical composition is formulated for delivery to the intestine.
14. The method of claim 10 , wherein the pharmaceutical composition is formulated for delivery to the colon.
15. The method of claim 1 , wherein one or more of the bacterial strains is lyophilized.
16. The method of claim 10 , wherein the pharmaceutical composition is in the form of a capsule.
17. The method of claim 10 , wherein the pharmaceutical composition further comprises a pH sensitive composition comprising one or more enteric polymers.